Search research articles
Contact Us
Filters
Showing results (41-50 of 61) with videos related to
Page
of 7
Sort By:
Cancer Discovery
|
April 8, 2024
The Pan-RAF-MEK Nondegrading Molecular Glue NST-628 Is a Potent and Brain-Penetrant Inhibitor of the RAS-MAPK Pathway with Activity across Diverse RAS- and RAF-Driven Cancers
Meagan B Ryan, Bradley Quade, Natasha Schenk, et al.
Molecular Cancer Therapeutics
|
November 8, 2014
Modeling targeted inhibition of MEK and PI3 kinase in human pancreatic cancer
Melissa R Junttila, Vidusha Devasthali, Jason H Cheng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 13, 2012
Bridging the gap between preclinical and clinical studies using pharmacokinetic-pharmacodynamic modeling: an analysis of GDC-0973, a MEK inhibitor
Harvey Wong, Laurent Vernillet, Amy Peterson, et al.
Journal of the National Cancer Institute
|
March 29, 2013
P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanoma
Christy C Ong, Adrian M Jubb, Diana Jakubiak, et al.
Journal of Medicinal Chemistry
|
June 2, 2015
Structure-Guided Design of Group I Selective p21-Activated Kinase Inhibitors
James J Crawford, Wendy Lee, Ignacio Aliagas, et al.
Plos One
|
May 10, 2012
Active PI3K pathway causes an invasive phenotype which can be reversed or promoted by blocking the pathway at divergent nodes
Jeffrey J Wallin, Jane Guan, Kyle A Edgar, et al.
The Journal of Cell Biology
|
October 8, 2008
Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents
Michael Degtyarev, Ann De Mazière, Christine Orr, et al.
Gastro Hep Advances
|
August 12, 2024
Evaluation of Protein Kinase cAMP-Activated Catalytic Subunit Alpha as a Therapeutic Target for Fibrolamellar Carcinoma
Stefanie S Schalm, Erin O'Hearn, Kevin Wilson, et al.
Cancer Discovery
|
October 3, 2019
Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma
Megan A Hatlen, Oleg Schmidt-Kittler, Cori Ann Sherwin, et al.
Molecular Cancer Therapeutics
|
March 10, 2012
ERK inhibition overcomes acquired resistance to MEK inhibitors
Georgia Hatzivassiliou, Bonnie Liu, Carol O'Brien, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 61) with videos related to
Sort By:
Page
of 7
Cancer Discovery
|
April 8, 2024
The Pan-RAF-MEK Nondegrading Molecular Glue NST-628 Is a Potent and Brain-Penetrant Inhibitor of the RAS-MAPK Pathway with Activity across Diverse RAS- and RAF-Driven Cancers
Meagan B Ryan, Bradley Quade, Natasha Schenk, et al.
Molecular Cancer Therapeutics
|
November 8, 2014
Modeling targeted inhibition of MEK and PI3 kinase in human pancreatic cancer
Melissa R Junttila, Vidusha Devasthali, Jason H Cheng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 13, 2012
Bridging the gap between preclinical and clinical studies using pharmacokinetic-pharmacodynamic modeling: an analysis of GDC-0973, a MEK inhibitor
Harvey Wong, Laurent Vernillet, Amy Peterson, et al.
Journal of the National Cancer Institute
|
March 29, 2013
P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanoma
Christy C Ong, Adrian M Jubb, Diana Jakubiak, et al.
Journal of Medicinal Chemistry
|
June 2, 2015
Structure-Guided Design of Group I Selective p21-Activated Kinase Inhibitors
James J Crawford, Wendy Lee, Ignacio Aliagas, et al.
Plos One
|
May 10, 2012
Active PI3K pathway causes an invasive phenotype which can be reversed or promoted by blocking the pathway at divergent nodes
Jeffrey J Wallin, Jane Guan, Kyle A Edgar, et al.
The Journal of Cell Biology
|
October 8, 2008
Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents
Michael Degtyarev, Ann De Mazière, Christine Orr, et al.
Gastro Hep Advances
|
August 12, 2024
Evaluation of Protein Kinase cAMP-Activated Catalytic Subunit Alpha as a Therapeutic Target for Fibrolamellar Carcinoma
Stefanie S Schalm, Erin O'Hearn, Kevin Wilson, et al.
Cancer Discovery
|
October 3, 2019
Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma
Megan A Hatlen, Oleg Schmidt-Kittler, Cori Ann Sherwin, et al.
Molecular Cancer Therapeutics
|
March 10, 2012
ERK inhibition overcomes acquired resistance to MEK inhibitors
Georgia Hatzivassiliou, Bonnie Liu, Carol O'Brien, et al.
Page
of 7